Literature DB >> 20647569

Requirement of the human T-cell leukemia virus p12 and p30 products for infectivity of human dendritic cells and macaques but not rabbits.

Valerio W Valeri1, Anna Hryniewicz, Vibeke Andresen, Kathy Jones, Claudio Fenizia, Izabela Bialuk, Hye Kyung Chung, Risaku Fukumoto, Robyn Washington Parks, Maria Grazia Ferrari, Christophe Nicot, Valentina Cecchinato, Frank Ruscetti, Genoveffa Franchini.   

Abstract

The identification of the genes necessary for human T-cell leukemia virus (HTLV-1) persistence in humans may provide targets for therapeutic approaches. We demonstrate that ablation of the HTLV-1 genes encoding p12, p30, or the HBZ protein, does not affect viral infectivity in rabbits and in this species, only the absence of HBZ is associated with a consistent reduction in virus levels. We observed reversion of the HTLV-1 mutants to the HTLV-1 wild-type genotype in none of the inoculated rabbits. In contrast, in macaques, the absence of HBZ was associated with reversion of the mutant virus to the wild-type genotype in 3 of the 4 animals within weeks from infection. Similarly, reversion to the wild type was observed in 2 of the 4 macaque inoculated with the p30 mutant. The 4 macaques exposed to the p12 knock remained seronegative, and only 2 animals were positive at a single time point for viral DNA in tissues. Interestingly, we found that the p12 and the p30 mutants were also severely impaired in their ability to replicate in human dendritic cells. These data suggest that infection of dendritic cells may be required for the establishment and maintenance of HTLV-1 infection in primate species.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20647569      PMCID: PMC2981536          DOI: 10.1182/blood-2010-05-284141

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

Review 1.  Multiple control levels of cell proliferation by human T-cell leukemia virus type 1 Tax protein.

Authors:  J M Mesnard; C Devaux
Journal:  Virology       Date:  1999-05-10       Impact factor: 3.616

2.  Protein isoforms encoded by the pX region of human T-cell leukemia/lymphotropic virus type I.

Authors:  I J Koralnik; A Gessain; M E Klotman; A Lo Monico; Z N Berneman; G Franchini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

3.  X-I and X-II open reading frames of HTLV-I are not required for virus replication or for immortalization of primary T-cells in vitro.

Authors:  D Derse; J Mikovits; F Ruscetti
Journal:  Virology       Date:  1997-10-13       Impact factor: 3.616

4.  Establishment of HTLV-I-infected cell lines from French, Guianese and West Indian patients and isolation of a proviral clone producing viral particles.

Authors:  C Nicot; T Astier-Gin; E Edouard; E Legrand; D Moynet; A Vital; D Londos-Gagliardi; J P Moreau; B Guillemain
Journal:  Virus Res       Date:  1993-12       Impact factor: 3.303

5.  The human T-cell leukemia/lymphotropic virus type 1 p12I proteins bind the interleukin-2 receptor beta and gammac chains and affects their expression on the cell surface.

Authors:  J C Mulloy; R W Crownley; J Fullen; W J Leonard; G Franchini
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  The human T-cell leukemia/lymphotropic virus type I p12I protein cooperates with the E5 oncoprotein of bovine papillomavirus in cell transformation and binds the 16-kilodalton subunit of the vacuolar H+ ATPase.

Authors:  G Franchini; J C Mulloy; I J Koralnik; A Lo Monico; J J Sparkowski; T Andresson; D J Goldstein; R Schlegel
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo.

Authors:  N D Collins; G C Newbound; B Albrecht; J L Beard; L Ratner; M D Lairmore
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

8.  Dendritic cells from patients with tropical spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte proliferation.

Authors:  S E Macatonia; J K Cruickshank; P Rudge; S C Knight
Journal:  AIDS Res Hum Retroviruses       Date:  1992-09       Impact factor: 2.205

9.  Construction and characterization of infectious human T-cell leukemia virus type 1 molecular clones.

Authors:  J T Kimata; F H Wong; J J Wang; L Ratner
Journal:  Virology       Date:  1994-11-01       Impact factor: 3.616

10.  Polymyositis, arthritis, and uveitis in a macaque experimentally infected with human T lymphotropic virus type I.

Authors:  M A Beilke; V Traina-Dorge; J D England; J L Blanchard
Journal:  Arthritis Rheum       Date:  1996-04
View more
  63 in total

1.  Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission.

Authors:  Nancy Van Prooyen; Heather Gold; Vibeke Andresen; Owen Schwartz; Kathryn Jones; Frank Ruscetti; Stephen Lockett; Prabhakar Gudla; David Venzon; Genoveffa Franchini
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-12       Impact factor: 11.205

2.  Distinct transformation tropism exhibited by human T lymphotropic virus type 1 (HTLV-1) and HTLV-2 is the result of postinfection T cell clonal expansion.

Authors:  Priya Kannian; Han Yin; Rami Doueiri; Michael D Lairmore; Soledad Fernandez; Patrick L Green
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

3.  Human T-lymphotropic type 1 virus p30 inhibits homologous recombination and favors unfaithful DNA repair.

Authors:  Hicham H Baydoun; Joanna Pancewicz; Christophe Nicot
Journal:  Blood       Date:  2011-03-22       Impact factor: 22.113

4.  Human T lymphotropic virus type 1 regulatory and accessory gene transcript expression and export are not rex dependent.

Authors:  Min Li; Priya Kannian; Han Yin; Matthew Kesic; Patrick L Green
Journal:  AIDS Res Hum Retroviruses       Date:  2011-08-05       Impact factor: 2.205

5.  Suppression of HTLV-1 replication by Tax-mediated rerouting of the p13 viral protein to nuclear speckles.

Authors:  Vibeke Andresen; Cynthia A Pise-Masison; Uma Sinha-Datta; Marcia Bellon; Valerio Valeri; Robyn Washington Parks; Valentina Cecchinato; Risaku Fukumoto; Christophe Nicot; Genoveffa Franchini
Journal:  Blood       Date:  2011-06-15       Impact factor: 22.113

Review 6.  Hijacking the T-cell communication network by the human T-cell leukemia/lymphoma virus type 1 (HTLV-1) p12 and p8 proteins.

Authors:  Nancy Van Prooyen; Vibeke Andresen; Heather Gold; Izabela Bialuk; Cynthia Pise-Masison; Genoveffa Franchini
Journal:  Mol Aspects Med       Date:  2010-07-29

7.  The human T-cell leukemia virus type-1 tax oncoprotein dissociates NF-κB p65RelA-Stathmin complexes and causes catastrophic mitotic spindle damage and genomic instability.

Authors:  Aditi Malu; Tetiana Hutchison; Laçin Yapindi; Katie Smith; Katherine Nelson; Rachel Bergeson; Jordan Pope; Megan Romeo; Carolyn Harrod; Lee Ratner; Carine Van Lint; Robert Harrod
Journal:  Virology       Date:  2019-07-03       Impact factor: 3.616

8.  The human T-cell leukemia virus type-1 p30II protein activates p53 and induces the TIGAR and suppresses oncogene-induced oxidative stress during viral carcinogenesis.

Authors:  Megan Romeo; Tetiana Hutchison; Aditi Malu; Averi White; Janice Kim; Rachel Gardner; Katie Smith; Katherine Nelson; Rachel Bergeson; Ryan McKee; Carolyn Harrod; Lee Ratner; Bernhard Lüscher; Ernest Martinez; Robert Harrod
Journal:  Virology       Date:  2018-02-20       Impact factor: 3.616

9.  Human T-cell leukemia/lymphoma virus type 1 p30, but not p12/p8, counteracts toll-like receptor 3 (TLR3) and TLR4 signaling in human monocytes and dendritic cells.

Authors:  Claudio Fenizia; Martina Fiocchi; Kathryn Jones; Robyn Washington Parks; Michele Ceribelli; Sebastien A Chevalier; Dustin Edwards; Francis Ruscetti; Cynthia A Pise-Masison; Genoveffa Franchini
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

10.  PA28γ is a novel corepressor of HTLV-1 replication and controls viral latency.

Authors:  Nga Ling Ko; John M Taylor; Marcia Bellon; Xue Tao Bai; Sergey P Shevtsov; Miroslav Dundr; Christophe Nicot
Journal:  Blood       Date:  2012-10-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.